Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: The spontaneously hypertensive rat

Basic and Clinical Pharmacology and Toxicology

Volumn 102, Issue 6, 2008, Pages 527-532

  Liu, Li Li ^a   Yang, Jie ^a   Lei, Ge Fei ^a   Wang, Gui Ju ^a   Wang, Yu Wei ^a   Sun, Ruo Peng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; DOPAMINE; HISTAMINE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HISTAMINE RELEASE; LEARNING; MALE; MAZE TEST; MEMORY; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TASK PERFORMANCE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; HISTAMINE; INJECTIONS, INTRAPERITONEAL; LEARNING; MALE; MAZE LEARNING; MEMORY; PREFRONTAL CORTEX; PROPYLAMINES; RATS; RATS, INBRED SHR; WATER;

ANIMALIA; RATTUS;

EID: 43749098306     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00230.x     Document Type: Article

References (48)

1. Swanson J, Castellanos FX, Murias M. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol 1998 8 : 263 71.
2. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005 57 : 1215 20.
3. Gitten JG, Winer JL, Festa EK, Heindel WC. Conditional associative learning of spatial and objective information in children with attention deficit/hyperactivity disorder. Child Neuropsychol 2006 12 : 39 56.
4. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 2000 24 : 31 9.
5. Russel VA. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behav Brain Res 2002 130 : 191 6.
6. Prediger RD, Pamplona FA, Fernandes D, Takahashi RN. Caffeine improves spatial learning deficits in an animal model of attention deficit hyperactivity disorder (ADHD) - the spontaneously hypertensive rat (SHR). Int J Neuropsychopharmacol 2005 8 : 583 94.
7. Wyss JM, Chambless BD, Kadish I, van Groen T. Age-related decline in water maze learning and memory in rats: strain differences. Neurobiol Aging 2000 21 : 671 81.
8. De Bruin NM, Kiliaan AJ, De Wilde MC, Broersen LM. Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats. Neurobiol Learn Mem 2003 80 : 63 79.
9. Nakamu EC. Deficits of spatial learning and working memory in spontaneously hypertensive rats. Behav Brain Res 1996 74 : 217 27.
10. Sutterer JR, Perry J, DeVito W. Two-way shuttle box and lever-press avoidance in the spontaneously hypertensive and normotensive rat. J Comp Physiol Psychol 1980 94 : 155 63.
11. Castellanos FX, Tannock R. Neuroscience of attentiondeficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci 2002 3 : 617 28.
12. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998 18 : 5901 7.
13. Solanto MV. Dopamine dysfunction in ADHD: integrating clinical and basic neuroscience research. Behav Brain Res 2002 130 : 65 71.
14. Swanson JM, Flodman P, Kennedy J, Spence MA, Moyzis R, Schuck S et al. Dopamine genes and ADHD. Neurosci Biobehav Rev 2000 24 : 21 5.
15. Krause KH, Dresel SH, Krauser J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000 285 : 107 10.
16. Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996 35 : 264 72.
17. Papa M, Diewald L, Carey MP, Esposito FJ, Girondi Carnevale UA, Sadile AG. A rostro-caudal dissociation in the dorsal and ventral striatum of the juvenile SHR suggests an anterior hypo- and posterior hyperfunctioning mesocorticolimbic system. Behav Brain Res 2002 130 : 171 9.
18. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AFT, Kelley AE, Schmeichel B et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006 60 : 1111 20.
19. 3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 2002 131 : 151 61.
20. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 2004 28 : 771 84.
21. Arnsten AF, Steere JC, Hunt RD. The contribution of alpha-2 noradrenergic mechanisms of prefrontal cortical cognitive function: potential significance for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1996 53 : 448 55.
22. Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AF. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 2002 22 : 8771 7.
23. Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006 67 (suppl 8 7 12.
24. 3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004 103 : 1 20.
25. Viggiano D, Ruocco LA, Arcieri S, Sadile AG. Involvement of norepinephrine in the control of activity and attentive processes in animal models of attention deficit hyperactivity disorder. Neural Plast 2004 11 : 133 49.
26. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Neurosci Rev 2003 4 : 121 30.
27. 2 receptors. Neurosci Res 2007 57 : 306 13.
28. 3 receptor antagonists/inverse agonists. Expert Opin Investig Drugs 2005 14 : 223 41.
29. 3 receptor drugs. Nat Med 2005 4 : 107 20.
30. Horner WE, Johnson DE, Schmidt AW, Rollema H. Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol 2007 558 : 96 7.
31. Li XM, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 1998 136 : 153 61.
32. Zhang W, Perry KW, Wong DT, Potts B, Tollefson GD, By-master FP. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000 23 : 250 62.
33. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, New York 1997.
34. Roof RL, Stein DG. Gender differences in Morris water maze performance depend on task parameters. Physiol Behav 1999 68 : 81 6.
35. 3 autoreceptors during handling stress in the prefrontal cortex of the rat. Synase 2002 43 : 238 43.
36. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002 27 : 699 711.
37. Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology 2006 50 : 755 60.
38. Russell VA. Dopamine hypofunction possibly results from a defect in glutamate-stimulated release of dopamine in the nucleus accumbens shell of a rat model for attention deficit hyperactivity disorder - the spontaneously hypertensive rat. Neurosci Behav Rev 2003 27 : 671 82.
39. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001 63 : 637 72.
40. 3-receptor antagonist. J Pharmacol Exp Ther 1998 287 : 658 66.
41. 3-receptor antagonist, of learning and memory in an elevated plus-maze test in mice. Naunyn Schmiedebergs Arch Pharmacol 1998 357 : 508 13.
42. Passini MB, Bacciottini L, Mannaioni PF, Blandina P. Central histaminergic system and cognition. Neurosci Biobehav Rev 2000 24 : 107 13.
43. 3 receptors depress synaptic transmission in the corticostriatal pathway. Neuropharmacology 2001 40 : 106 13.
44. 1 receptors in the nucleus basalis magnocellularis: a dual probe microdialysis study in the freely moving rat. Eur J Neurosci 2001 13 : 68 78.
45. Dringenberg H, Kuo M. Histaminergic facilitation of electrocorticographic activation: role of basal forebrain, thalamus, and neocortex. Eur J Neurosci 2003 18 : 2285 91.
46. Gabriele C, Patrizio B, Ken M, Daniele N. Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain. Eur J Neucrosci 2006 24 : 1633 44.
47. Gibson AP, Bettinger TL, Patel NC, Crismon ML. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006 40 : 1134 42.
48. Jan KB, David M, Marina D, Christopher G. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 2007 61 : 694 9.